Durable response to a second course of immunotherapy in a long-term survivor with relapsed small cell lung cancer

Chemoimmunotherapy (CIT) has significantly improved outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC). However, relapses are common. Long-term survival (LTS) is possible for some patients with ES-SCLC treated with CIT regimens; however, the optimal duration for maintenance immunotherapy remains unknown. There is no data on optimal treatment options if LTS patients relapse while off therapy. Here, we are presenting a patient with ES-SCLC, who stopped treatment at 2 years, with disease relapse shortly afterwards. She was treated with a second course of single-agent immunotherapy with another durable remission.